Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile posts 91–120
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Narrowing post #89, because the general version has more than one answer.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Scoping that to what I have actually seen rather than what I have read.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
Happy to expand any of that if it is the useful part.
The question underneath semaglutide and gastric emptying is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Collapsed as off-topic by two members at trust level 3 or above
Sensible. I would want the same detail before I acted on it either.
Post #93 answers the question as asked. The question underneath it is different.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
I have left out the parts I could not verify.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
I am describing what is, rather than arguing for what should be.
Semaglutide and gastric emptying is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Coming back to post #97, because the follow-up matters more than the original answer.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
A qualification I should have led with rather than closed on.
Post #101 is right about the mechanism and I think understates the practical bit.
Counterpoint on semaglutide and gastric emptying, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.
I would treat the number as indicative rather than as a measurement.
Reading rather than answering, but this is the post I would point somebody at.
On semaglutide and gastric emptying I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Collapsed as off-topic by two members at trust level 3 or above
Confirming post #105 from a second method, which matters more than confirming it from a second person.
Summarising the semaglutide and gastric emptying thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
I had read the opposite somewhere and cannot now find where, which tells me something.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
I would put this at better than even and not much better.
Post #108 is the version of this I will quote in future. One addition.
On semaglutide and gastric emptying, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
Where I part company with post #110, and it is a narrow parting.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
I would rather say I do not know than round it up to an answer.
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
No notes. Posting so the count is not one.
Post #114 put the caveat in the right place and I want to underline it.
Semaglutide and gastric emptying was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Collapsed as off-topic by two members at trust level 3 or above
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Caveat: everything above assumes the paperwork is what it says it is.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
The reasoning is more useful than the number, which is why I have shown it.
I would be cautious about generalising from the semaglutide and gastric emptying example above. It is a good example. It is one example.